IPF Cough: Opioid-Based Approach Tested
Researchers examine oral nalbuphine for chronic cough in IPF, using objective digital monitoring and patient-reported measures.
By
Kathryn Wighton
January 28, 2026
Clinical Scorecard: IPF Cough: Opioid-Based Approach Tested
At a Glance
Category Detail
Condition Idiopathic Pulmonary Fibrosis (IPF) with Chronic Cough Key Mechanisms Oral κ-opioid receptor agonist (nalbuphine) targeting cough frequency Target Population Adults with IPF and chronic cough lasting at least 8 weeks Care Setting Multinational, randomized, double-blind, placebo-controlled clinical trial
Key Highlights
Dose-dependent reductions in cough frequency observed with nalbuphine 60% reduction in cough frequency with 108 mg dose at 6 weeks Improvements in cough severity and quality of life in higher dose groups Study involved 165 patients across 52 sites in 10 countries Common adverse events included nausea, vomiting, and dizziness Guideline-Based Recommendations
Diagnosis
Cough severity numerical rating scale score of 4 or higher Prespecified pulmonary function criteria must be met Management
Consider nalbuphine extended release for chronic cough in IPF patients Monitoring & Follow-up
Continuous digital cough monitoring for 24 hours to assess cough frequency Risks
Mild adverse events primarily during dose titration, potential for bias in missing data Patient & Prescribing Data
Median age 71 years, 72% male, 77% on antifibrotic therapy
Effective cough frequency reduction observed with higher nalbuphine doses
Clinical Best Practices
Monitor patients for adverse events during dose titration Assess patient-reported outcomes alongside objective cough measurements Consider long-term efficacy and safety in future studies Related Resources & Content
